Olorigliflozin - HEC Pharm
Alternative Names: 14C-Rongliflozin; DJT-1116PG; HEC-44616; Rongliflozin pyroglutamateLatest Information Update: 19 May 2025
At a glance
- Originator HEC Pharm
- Developer Sunshine Lake Pharma
- Class Antihyperglycaemics; Small molecules
- Mechanism of Action Sodium-glucose transporter 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Type 2 diabetes mellitus
Most Recent Events
- 31 Dec 2023 Preregistration for Type 2 diabetes mellitus in China (PO), in December 2023
- 31 Dec 2023 Efficacy and adverse events data from a phase IIIa trial in Type 2 diabetes mellitus released by Sunshine Lake Pharma, before December 2023
- 31 Dec 2023 Efficacy and adverse events data from a phase IIIb trial in Type 2 diabetes mellitus released by Sunshine Lake Pharma, before December 2023